<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532142</url>
  </required_header>
  <id_info>
    <org_study_id>EK-04-010-0204</org_study_id>
    <nct_id>NCT00532142</nct_id>
  </id_info>
  <brief_title>The ROVO Study: Radial Optic Neurotomy for CVO</brief_title>
  <official_title>A Multicenter Trial for Surgical Treatment of Central Retinal Vein Occlusion - Radial Optic Neurotomy for CVO The ROVO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rudolf Foundation Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rudolf Foundation Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ROVO study is a prospective, placebocontrolled and randomised study designed to evaluate&#xD;
      the effect of radial optic neurotomy in central vein occlusion, versus triamcinolone&#xD;
      acetonide. 240 patients with a visual acuity &lt; 0.5 Snellen will be randomised. Patients are&#xD;
      treated with either RON, or a single intravitreal injection of 4 mg triamcinolone acetonide,&#xD;
      or a placebo treatment - a &quot;sham&quot; injection of intravitreal triamcinolone. Patients will be&#xD;
      examined regularly over a period of one year.&#xD;
&#xD;
      Best corrected visual acuity for far and near, as well as clinical examinations, fluorescein-&#xD;
      and indocyanine green angiograms, optical coherence tomography, and perimetry, are performed&#xD;
      pre- and postoperatively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eyes with an improvement of more than 15 letters (approximately &gt; 3 lines of visual acuity gain) after one year as compared to baseline</measure>
  </primary_outcome>
  <condition>Central Retinal Vein Occlusion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Triamcinolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radial Optic Neurotomy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo - Sham Intravitreal Injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Onset of CVO not longer than 12 months&#xD;
&#xD;
          -  On FLA 1. nonperfused - (greater than 10 disc area of nonperfusion) 2. perfused -&#xD;
             visual acuity lower than 0.1 Snellen,or 3. perfused with no improvement of visual&#xD;
             acuity over 4 weeks)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Dense cataract* (grade 3 and 4) which precludes judgement of the fundus.&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Allergy against Fluoresceine or Indocyanine green&#xD;
&#xD;
               -  Unable to come for follow up visit&#xD;
&#xD;
               -  Presence of other severe retinopathy or&#xD;
&#xD;
               -  Presence of advanced optic atrophy or uncontrolled glaucoma.&#xD;
&#xD;
               -  Visual acuity higher than 0.5 Snellen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Susanne Binder, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>no affiliation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rudolf foundation Clinic</name>
      <address>
        <city>Vienna</city>
        <zip>A1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>October 29, 2009</last_update_submitted>
  <last_update_submitted_qc>October 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

